相关实验视频

Updated: Jan 10, 2026

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)

Published on: January 10, 2025

纳米载体增强的simvastatin调节AMPK-ULK1通路和阿尔茨海默病模型中的氧化应激

Ali Mohamed Afify¹, Elsayed K El-Sayed¹, Aliaa Ismail²

¹Department of Pharmacology and Toxicology, Faculty of Pharmacy, Helwan University, Ain Helwan, Cairo 11795, Egypt.

European journal of pharmacology

|November 28, 2025

概括

辛瓦斯塔丁 (Simva) 通过增强自和减少氧化应激和炎症,对阿尔茨海默病 (AD) 产生神经保护作用. 在AD大鼠模型中,Simva的纳米载体输送进一步提高了其治疗潜力.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
生物化学生物化学

背景情况:

阿尔茨海默病 (AD) 涉及海马和大脑皮层的退化,标志着胆能神经元损失,Aβ斑块,氧化应激,神经炎症和自功能受损.
在老鼠中暴露于化 (AlCl3) 作为研究AD病变的模型.

研究的目的:

在AlCl3诱导的老鼠阿尔茨海默病模型中研究simvastatin (Simva) 的神经保护作用.
评估基于纳米载体的输送系统对增强Simva在AD中的大脑药理学活性的有效性.

主要方法:

成年雄性Sprague Dawley大鼠被分为四组:对照组,AlCl3诱导的AD,Simva治疗和Simva纳米载体治疗.
治疗包括28天内在AlCl3注射之前口服Simva或其纳米载体.
评估了自标志物 (p-AMPK,p-ULK1,LC3-II,ULK1),氧化应激标志物 (MDA,GSH),炎症标志物 (TNF-α,IL-1β),乙胆 (ACh) 水平和乙胆酶 (AChE) 基因表达.
免疫组织化学和组织病理学分析用于量化Aβ斑块并评估神经元退化和质激活.

主要成果:

辛巴斯塔丁及其纳米载体显著增强了自,减少了氧化应激和炎症,并增加了ACH水平,同时抑制了ACHE表达.
西姆瓦治疗导致Aβ斑块的显著减少.
西姆瓦纳米载体组没有可检测的Aβ斑块和近乎正常的海马体结构,表明显著的神经保护.
组织病理学分析显示,在接受Simva治疗的组中,神经元退化和质激活减少.

结论:

在阿尔茨海默病的老鼠模型中,西姆瓦斯塔丁通过抗氧化,抗炎和自机制显示出显著的神经保护作用.
通过纳米载体介导的Simva的输送增强了其治疗疗效,为阿尔茨海默病治疗提供了一个有前途的策略.
这项研究强调了纳米配方他类药物作为AD等神经退行性疾病的可行治疗方法的潜力.

关键词:

() () () () () () () () () () () () () () () () ) () () ) () () ) () () ) () () ) () ) () () ) () () ) () () ) () ) () ) () ) () ) () ) () ) () ) () ()阿尔茨海默病的疾病阿尔茨海默病的疾病.自自是一种自的过程.纳米载体纳米载体是什么它们是老鼠,老鼠,老鼠.西姆瓦斯塔丁是一种

更多相关视频

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein

Published on: July 29, 2018

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer's Disease: Overview

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...